Senescent Cell Removal Unleashes NK Cells Shown to Fight Cancer and Viruses in Animal Models

PR Newswire
April 22, 2025

Immorta Bio, a longevity biotech company, announced new findings showing its SenoVax™ senolytic immunotherapy significantly boosts natural killer (NK) cell numbers and activity by clearing senescent cells. Covered under newly filed patent #63/789,097, this breakthrough may enhance the body’s ability to fight cancer and viral infections. Preclinical studies reveal SenoVax not only boosts immune response but may transfer cancer-fighting benefits between animals. Currently in development for lung cancer, SenoVax is designed to work alone or enhance existing therapies by removing the “senescent shield” protecting tumors.

Read Full Article

Explore More

May 5, 2025

Immorta Bio Presents SenoVax™ Cancer Senolytic Immunotherapy Preclinical Data at American Association of Immunologists Meeting

March 13, 2025

Immorta Bio Presents SenoVax™ Mediated Tumor Remission Data at International Biotechnology Conference

March 11, 2025

Reduction of Chemotherapy Associated Accelerated Aging by ImmortaSome™ Personalized Exosome Rejuvenation

See all news
Get The Latest News and Developments On Our Longevity Journey
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
By subscribing, you are acknowledging your consent to receive  Immorta Bio newsletters
19505 Biscayne Blvd, Ste 2350 Aventura, Florida 33180
305 632-2939
info@immortabio.com